Advaxis, SELLAS Ink Licensing Agreement for WT1 Antigen-Targeting Immunotherapy – Drug Discovery & Development
Drug Discovery & Development |
Advaxis, SELLAS Ink Licensing Agreement for WT1 Antigen-Targeting Immunotherapy
Drug Discovery & Development Advaxis, Inc. and SELLAS Life Sciences Group, both late-stage biopharmaceutical companies focused on developing cancer immunotherapies, today announced that Advaxis has granted SELLAS a license to develop a novel cancer immunotherapy agent … |
